Projection to latent structures regression and its application to Mach–Zehnder interferometer optical fiber sensors for acetone detection

Autor: Hernández-Guerrero, L.D., Castillo-Mixcóatl, J., Muñoz-Aguirre, S., Rodríguez-Torres, M., Ramírez-Sánchez, E., Beltrán-Pérez, G.

Publikováno v: In Optics and Lasers in Engineering January 2025 184 Part 2

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Autor: Ciuleanu, T. ^*, Bazin, I., Lungulescu, D., Miron, L., Bondarenko, I., Deptala, A., Rodriguez-Torres, M., Giantonio, B., Fox, N.L., Wissel, P., Egger, J., Ding, M., Kalyani, R.N., Humphreys, R., Gribbin, M., Sun, W. ^{*, *}

Publikováno v: In Annals of Oncology April 2016 27(4):680-687

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

Autor: Rodriguez ‐ Torres, M.¹, Glass, S.², Hill, J.³, Freilich, B.⁴, Hassman, D.⁵, Di Bisceglie, A. M.⁶, Taylor, J. G.⁷, Kirby, B. J.⁷, Dvory ‐ Sobol, H.⁷, Yang, J. C.⁷, An, D.⁷, Stamm, L. M.⁷, Brainard, D. M.⁷, Kim, S.⁸, Krefetz, D.⁹, Smith, W.¹⁰, Marbury, T.¹¹, Lawitz, E.¹²

Publikováno v: Journal of Viral Hepatitis. Aug2016, Vol. 23 Issue 8, p614-622. 9p.

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C ( NUCLEAR).

Autor: Lawitz, E. J.¹, Rodriguez‐Torres, M.², Denning, J.³, Mathias, A.³, Mo, H.³, Gao, B.³, Cornpropst, M. T.⁴, Berrey, M. M.⁵, Symonds, W. T.³

Publikováno v: Journal of Viral Hepatitis. Oct2013, Vol. 20 Issue 10, p699-707. 9p. 1 Diagram, 4 Charts, 2 Graphs.

Telaprevir for previously untreated chronic hepatitis C virus infection

Autor: Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J. M., Pol S., Serfaty L., Trépo C., Zarski J. P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben Ari Z., Maor Y., Safadi R., Zuckerman E., Colombo M., Baka Cwierz B., Gladysz A., Janczewska Kazek E., Jablkowski M., Krycka W., Diago M., Esteban Mur R., Sanchez Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., Zein N., ANDREONE, PIETRO

A B S T R AC T Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, has shown improved efficacy, with poten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052a883adee96e1a0f587feb78d8287d
http://hdl.handle.net/11585/129215